Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/23/2025 | Buy → Hold | Needham | |
| 6/4/2025 | $61.00 → $65.00 | Buy | Needham |
| 4/29/2025 | $30.00 | Buy → Hold | TD Cowen |
| 2/18/2025 | $42.00 → $60.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/10/2025 | $24.00 → $25.00 | Neutral → Sell | Citigroup |
| 1/7/2025 | $35.00 | Buy | BTIG Research |
| 12/17/2024 | $42.00 | Overweight | Morgan Stanley |
| 11/14/2024 | Buy → Underperform | BofA Securities |
144 - Hims & Hers Health, Inc. (0001773751) (Subject)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
Unlocking a New Dimension of Personalized Digital Healthcare for Millions Across Europe Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced a significant step in its global expansion through its agreement to acquire ZAVA, a leading digital health platform in Europe. This strategic move will expand Hims & Hers' footprint in the United Kingdom and will officially launch the company into Germany, France, and Ireland, with more markets anticipated soon. This acquisition is expected to accelerate Hims & Hers' vision to deliver the same seamless, personalized care experience it has successfully built in the U.S. to millions more people globally. Hims
Hims & Hers Health, Inc. (NYSE:HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250522903885/en/Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only). "We are always looking for long-term, sustainable ways to increase access to care for our customers," said Andrew Dudum, CEO and co-founder of
Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
Needham downgraded Hims & Hers Health from Buy to Hold
Needham reiterated coverage of Hims & Hers Health with a rating of Buy and set a new price target of $65.00 from $61.00 previously
TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00